M&A Deal Summary

Callitas Therapeutics Acquires M Diagnostics

On February 19, 2015, Callitas Therapeutics acquired medical products company M Diagnostics

Acquisition Highlights
  • This is Callitas Therapeutics’ 1st transaction in the Medical Products sector.
  • This is Callitas Therapeutics’ 1st transaction in Canada.
  • This is Callitas Therapeutics’ 1st transaction in Alberta.

M&A Deal Summary
Date 2015-02-19
Target M Diagnostics
Sector Medical Products
Buyer(s) Callitas Therapeutics
Deal Type Add-on Acquisition

Target

M Diagnostics

Calgary, Alberta, Canada
M Diagnostics, Inc. is a manufacturer of eMosquito monitoring devices to measure blood glucose, primarily by diabetics.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Callitas Therapeutics

Vancouver, British Columbia, Canada
Category Company
Founded 2003
Sector Healthcare Services
Revenue 1M CAD (2017)
DESCRIPTION

Callitas Health is focuses on providing biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes. Callitas Health was founded in 2003 and is based in Vancouver, Canada.

DEAL STATS #
Overall 1 of 4
Sector (Medical Products) 1 of 2
Type (Add-on Acquisition) 1 of 3
State (Alberta) 1 of 1
Country (Canada) 1 of 2
Year (2015) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-28 RX Global Capital

British Columbia, Canada

RX Global Capital, Inc. is a developer of controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss, and several other medical applications.

Buy -
Mergr

Product

Company

Legal